Sepracor, Inc. (SEPR)

[surf1944]

Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals
Monday July 14, 8:21 am ET

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced its intention to fully support the Pharmaceutical Research and Manufacturers of America’s (PhRMA) updated and enhanced Code on Interactions with Healthcare Professionals (PhRMA Code). The purpose of the revised PhRMA Code includes addressing interactions with respect to marketed pharmaceutical products and related pre-launch activities, and the industry’s relationships with clinical investigators and others as they relate to the clinical research process.

“Sepracor has always been committed to responsible and ethical interactions with healthcare professionals,” said Adrian Adams, President and Chief Executive Officer of Sepracor. “This new PhRMA Code serves to underscore the importance of maintaining an appropriate, two-way, educational or informational communication between healthcare professionals and pharmaceutical industry representatives. During the next six months, we intend to update our policies and procedures to ensure compliance with not only the letter, but the spirit, of the standards set forth in the new PhRMA Code.”